#P-15-Peptide

2 stories

Research April 27, 2026 · View digest

PubMed Review: "Therapeutic Peptides in Orthopaedics — Applications, Challenges, and Future Directions"

A 2025-2026 PubMed-indexed review (PMID 41490200) consolidates the orthopedics-focused therapeutic peptide literature, covering bone graft peptides (P-15, BMP-2 mimetics), tendon repair peptides (BPC-157, TB-500), cartilage peptides (Cartalax, anti-myostatin agents), and clinical translation challenges. Cerapedics' PearlMatrix P-15 is highlighted as one of the few FDA-cleared peptide-enhanced orthopedic products — context for the company's Vizient supplier deal earlier this week.

Industry April 25, 2026 · View digest

Cerapedics Announces Vizient Supplier Agreement for PearlMatrix® P-15 Peptide-Enhanced Bone Graft for Lumbar Spine Fusion

Cerapedics, Inc. announced April 24 a supplier agreement with Vizient for PearlMatrix® P-15 Peptide Enhanced Bone Graft, a Class III drug-device combination product for adult patients with degenerative disc disease in the lumbar spine. The deal extends access to Vizient's network of academic medical centers, community hospitals, and integrated health delivery networks. PearlMatrix uses a 15-amino-acid peptide (a fragment of Type I collagen) bound to anorganic bone mineral as a bone growth accelerator — one of the few peptide-enhanced devices on the U.S. orthopedics market.